Vaccine News

With the global resurgence of the highly contagious measles virus, Southeast Asia is being affected by infected international travelers, including the city-state of the Republic of Singapore. In early 2026, Singapore's Communicable Diseases Agency (CDA) reported a significant increase in measles cases.

Despite historically high vaccination rates, measles remains a significant public health concern in Singapore.

By mid-February 2026, the CDA had recorded 13 confirmed measles cases for the year, including 11 in January alone, surpassing the 11 cases reported for the entire 2024 and nearing the 27 cases seen in 2025.

The CDA emphasized that all of the January cases involved individuals who were not fully vaccinated with the measles, mumps, and rubella (MMR) vaccine.

The vaccine has been compulsory for children since 1985, with the two-dose MMR regimen introduced in 1998.

While Singapore's robust public health system and high baseline coverage have so far limited widespread outbreaks among the six million residents, officials warn that sustained vigilance, including prompt reporting of suspected cases and strong adherence to vaccination, is essential to prevent outbreaks from escalating in our interconnected world.

As of February 22, 2026, proof of measles vaccination is not required for international visitors arriving in Singapore.

Seasonal influenza activity remains elevated across much of the United States, though trends vary regionally, with some areas seeing declines in influenza A and rises in influenza B cases.

Unfortunately, the U.S. Centers for Disease Control and Prevention (CDC) has reported six new influenza-associated pediatric deaths in its FluView surveillance update for Week 6 of 2026.

This data highlights the ongoing serious risks posed by the virus to children.

Of the reported deaths on February 14, 2026, five occurred during the current 2025-2026 flu season, bringing the total number of pediatric fatalities this season to 71. These deaths happened during Weeks 2, 4, and 5 (ending January 17, January 31, and February 7, 2026).

Four deaths were linked to influenza A viruses, three of which were subtyped as A(H3N2).

Additionally, one death from the previous 2024-2025 season was reported this week, associated with influenza A(H1N1), bringing that season's final pediatric death total to 290.

Following an update to the U.S. childhood immunization schedule issued by the CDC on January 5, 2026, the annual influenza vaccine for children is now recommended based on shared clinical decision-making between parents or guardians and healthcare providers, rather than as a routine recommendation for all children aged 6 months and older.

Among the children eligible for vaccination and with known vaccination status, approximately 90% of the reported pediatric deaths this season occurred in those who were not fully vaccinated against influenza.

Health officials stress that this approach allows families to consider individual risk factors—such as age, underlying medical conditions, and community flu activity—when deciding whether to vaccinate. The CDC continues to emphasize that flu vaccination remains a crucial prevention tool during ongoing virus circulation.

Vaccination coverage data from the previous 2024-2025 season highlights ongoing challenges: only 50.2% of U.S. children aged 6 months through 17 years received at least one dose of the flu vaccine—the lowest coverage in the past 15 seasons.

As of early February 2026, interim coverage for the current 2025-2026 season stands at approximately 47.5%, similar to the same point last season.

The CDC urges parents to speak with their child's healthcare provider promptly about flu vaccination and to seek early antiviral treatment if flu symptoms develop in high-risk children.

As of February 21, 2026, flu shots remain available at clinics and pharmacies throughout the USA. However, the nasal flu shot is sold out for this season.

Seasonal influenza continues to circulate at elevated levels across the United States in mid-February 2026, with health officials from the Centers for Disease Control and Prevention (CDC) noting a shift in the dominant strains driving infections.

According to the CDC's latest Weekly U.S. Influenza Surveillance Report for 2026, seasonal influenza activity remains high nationally. Influenza A activity is decreasing, while influenza B activity is increasing both nationwide and in most regions of the country. Influenza A(H3N2) viruses have been the most commonly reported subtype this season so far.

However, these trends show notable regional variability.

Regional differences are particularly evident in supplementary tracking tools.

The Walgreens Respiratory Index©, which monitors respiratory illness trends using prescription, testing, and over-the-counter product data from Walgreens locations, illustrates this variability in mid-February 2026.

Numerous states in the eastern portion of the country have shifted to green, indicating lower relative intensity compared to baseline levels. In contrast, states in western areas continue to show red, representing the highest intensity category.

The Index also highlights maximum intensity in several southern states, including Alabama, Arizona, Florida, and Mississippi, where respiratory illness activity—driven largely by ongoing flu circulation—remains at peak levels.

Health experts emphasize that while influenza A declines in many places, the rise in influenza B could sustain elevated activity or lead to prolonged circulation in certain regions.

Officials continue to recommend vaccination.

"This flu season is exceptionally active," commented Anita Patel, vice president of Pharmacy Services Development at Walgreens, in a January 2026 press release.

"To protect yourself and others, I encourage everyone to get vaccinated as soon as possible, wash your hands frequently, and if you're feeling symptoms, get tested right away," Patel says.

The CDC updates its FluView surveillance weekly, and activity levels can fluctuate. For the most current data, visit the CDC's FluView website.

Furthermore, when traveling abroad, check the CDC's Travel Health Notices for information on disease outbreaks in other countries and related travel vaccine options.

As a frequent airplane traveler who is concerned about catching the flu in crowded cabins with recycled air, I am thrilled by recent research on CR9114. This nasal spray delivers influenza-specific monoclonal antibodies.

This innovative product, if approved, could be ideal for high-exposure situations, such as flying during flu season, especially for travelers.

While modern commercial airplanes have high-efficiency ventilation systems that recirculate cabin air through HEPA filters, they don't remove all viruses. If an infected passenger is on board—especially one who is coughing or sneezing—flu virus transmission can still occur.

Published on February 4, 2026, in Science Translational Medicine, the study, led by researchers from Harvard in collaboration with Leyden Laboratories, demonstrates that the intranasal delivery of the broad-spectrum hemagglutinin antibody CR9114 is both safe and feasible.

In two Phase 1 trials involving healthy volunteers, repeated dosing (twice daily, given the approximately 3-hour nasal half-life) achieved sustained high antibody levels in the nose.

These recovered antibodies retained strong neutralizing activity against both influenza A and B viruses.

Importantly, this nasal spray is not a replacement for seasonal influenza vaccines but rather may offer a rapid, short-term immunoprophylactic option. By delivering high local antibody concentrations directly at the virus's entry point with small doses, CR9114 has shown early promise.

Previous preclinical tests on mice and macaques confirmed its safety and effectiveness against influenza challenge.

These findings lay the groundwork for future efficacy trials and provide proof of concept that intranasal antibodies can elicit efficacious passive immunity against influenza viruses.

For someone who dreads having post-flight sniffles turn into illness, this nasal spray could become an essential item to carry on board before flying.

The Public Health Agency of Canada (PHAC) recently aligned its travel health guidance with that of the U.S. Centers for Disease Control and Prevention (CDC), issuing Level 2 travel notices for Bolivia, Cuba, Seychelles, Sri Lanka, and Suriname due to increased chikungunya virus activity.

As of February 19, 2026, these Level 2 advisories, which call for enhanced precautions, address the higher-than-expected transmission rates of the mosquito-borne illness in these destinations.

These advisories follow an epidemiological alert issued by the Pan American Health Organization (PAHO) on February 10, 2026, which warned of a sustained increase in chikungunya cases across various parts of the Americas since late 2025 and into early 2026.

The alert highlights the re-emergence of local transmission in areas that had been free of the virus for several years, including regions of the Guiana Shield and parts of Florida.

Chikungunya, primarily spread by infected mosquitoes, causes symptoms such as sudden fever, severe joint pain, muscle aches, headaches, nausea, fatigue, and rashes. While rarely fatal, the disease can cause prolonged joint discomfort in some individuals.

In December 2013, the virus was detected for the first time in the Americas Region.

According to PAHO data and related reports, by early 2026 (specifically epidemiological week 4, around late January to early February), 7,150 chikungunya cases had been reported regionally, including 2,351 confirmed cases and 1 death.

Cuba reported a significant number of suspected cases early in the year, with updates indicating that 1,457 were suspected as of late January.

The PHAC and the CDC recommend that travelers to these countries take necessary precautions, such as avoiding mosquito bites. They note that vaccination against chikungunya is available at travel clinics as of February 2026.

The Pan American Health Organization (PAHO) recently announced it has partnered with the Ministry of Health, Wellness, and the Environment of Saint Vincent and the Grenadines to promote the rollout of the human papillomavirus (HPV) vaccine for school-aged children.

On February 11, 2026, PAHO stated that HPV vaccination is a crucial component of cervical cancer prevention, as persistent infections with high-risk HPV types account for the majority of cervical cancer cases throughout the Caribbean Islands.

This collaboration is particularly important in Saint Vincent and the Grenadines, where cervical cancer poses a significant public health challenge.

Recent data revealed that 17 women were diagnosed with cervical cancer in 2024, marking an 88.9% increase from 2023. An additional 17 new cases were recorded in the first nine months of 2025.

From 2020 to 2024, a total of 44 women succumbed to this vaccine-preventable disease.

In 2023, cervical cancer accounted for 12.7% of all cancers among women in Saint Vincent.

The situation is similarly alarming across the Caribbean region, including Cuba and Puerto Rico, which have one of the highest rates of cervical HPV infection globally, at approximately 16% among women, ranking second only to sub-Saharan Africa.

Every year, more than 78,000 women in the Americas are diagnosed with cervical cancer, leading to over 40,000 deaths, 83% of which occur in Latin America and the Caribbean.

Dr. Amalia Del Riego, PAHO/WHO Representative for Barbados and the Eastern Caribbean Countries, welcomed the strong community response to this initiative. "We congratulate the Ministry of Health for advancing the elimination strategy by actively engaging communities," she stated.

"This partnership builds on recent milestones in the country, including the introduction of HPV DNA testing for screening (launched in September 2025) and expanded access to diagnostic and treatment services."

These actions, from vaccination to screening and treatment, represent a holistic approach to eliminating cervical cancer, in line with PAHO and WHO regional and global goals for 2026.